Proceso de atención de enfermería en paciente adulto mayor con fibrosis pulmonar
Pulmonary fibrosis is a disease that belongs to the group of diffuse interstitial lung pathology, is of unknown cause, with poor prognosis and there are few therapeutic options. It usually affects men older than 50 years and these present with progressive signs and symptoms that will worsen during t...
שמור ב:
| מחבר ראשי: | |
|---|---|
| פורמט: | bachelorThesis |
| שפה: | spa |
| יצא לאור: |
2018
|
| נושאים: | |
| גישה מקוונת: | http://dspace.utb.edu.ec/handle/49000/4532 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
הוספת תג | סיכום: | Pulmonary fibrosis is a disease that belongs to the group of diffuse interstitial lung pathology, is of unknown cause, with poor prognosis and there are few therapeutic options. It usually affects men older than 50 years and these present with progressive signs and symptoms that will worsen during the course of the disease such as dyspnea on exertion and dry cough. In recent years, an increase in prevalence has been observed, probably due to the optimization of diagnostic methods and the increase in life expectancy. It is characterized by a progressive accumulation of extracellular matrix or interstitial tissue. These mediators have been identified to be able to focus them as a therapeutic target. Thanks to this, in recent years, new molecules have been developed, the most important being Nintedanid and Pirferidone. This last molecule has recently been approved by the EMA (European Medicines Agency) and is currently the treatment of choice for patients with mild-moderate IPF thanks to the good results it has shown in the clinical trials presented |
|---|